Radiotherapy Approach in the Treatment of Mycosis Fungoides: Principles and Recommendations

Gustavo N Marta*, Samir A Hanna and João Luís F da Silva

Department of Radiotherapy, Sírio-Libanês, Oncology Center, São Paulo, Brazil

Abstract

Background: Mycosis fungoides (T-cell non-Hodgkin’s lymphoma) is a quite rare neoplasia, which follows an indolent course, characterized by presenting epidermotropism in spite that there is a possibility of compromise of structures like lymph nodes and visceral organs. Its incidence increases starting from the fourth decade of life with posterior drop after more or less the age of 80, having preference for men.

Objective: To analyze the role of radiotherapy in the therapeutic approach of patients with diagnosis of mycosis fungoides.

Conclusions: Radiotherapy is indicated for patients suffering from mycosis fungoides in all stages especially when the disease has affected more than 50% of the body surface. Starting from stage IB, total skin irradiation is employed with a dose of 30 to 36 Gy with boost at medical criterion.

Introduction

Mycosis Fungoides (MF) (T-cell non-Hodgkin’s lymphoma) is a quite rare pathology that strikes approximately 1,400 individuals a year in the United States of America [1]. It incidence increases starting from the fourth decade of life with posterior drop after more or less the age of 80, having preference among black men [2-4].

Following an indolent course, the disease is characterized by presenting epidermotropism, in spite that there is a possibility of compromise of structures like lymph nodes and visceral organs [5,6]. Its etiology still remains uncertain and there is no real proof of the cause-effect relation with the following risk factors: cytomegalovirus infection and HTLV-1 (Human T-lymphotropic virus type I) infection, smoking, alcoholism and pesticide exposure and radiation [7-9]. The main prognostic factor is the disease staging (Table 1), [10] mainly in what refers to extent and type of involvement in the skin and the presence or absence of extracutaneous disease.

This study has the objective of demonstrating the role of radiotherapy in the therapeutic approach of patients with diagnosis of mycosis fungoides.

Recommendations of Treatment in Accordance with Staging

Stage IA


MF is extremely sensitive to radiation. Low energy x-ray (100 kvp) can be applied in the treatment of isolated lesions although its use may be limited as a consequence of acute and late toxicity. Electron radiotherapy technique is the standard for the approach of these lesions. It presents complete response rate of 40 to 98%. The treatment margin is 2 cm with total dose of 15 to 25 Gy administered in 3 weeks. Generally it is indicated after treatment failure with nitrogenated mustard and topical corticoid [15].

Stage IB/IIA/IIB

For stages IB – IIB patients there are innumerable treatment forms that vary from radiotherapy of the entire skin with electrons (total skin irradiation – TSI), topical chemotherapy (nitrogenated mustard or carmustine), phototherapy (PUVA or UVB), topical corticoid up to systemic retinoids, interferon and systemic chemotherapy [16,17].

TSI has complete response rate of 80 – 97%. It can be employed as initial therapy in the presence of thick lesions for presenting greater therapeutic effect than topical chemotherapy and phototherapy. Normally it is used in patients with history of rapid disease progression or under the effect of treatment failure after initial topical approach [18-20].

Goujon et al. [21] in a retrospective study with 68 initial stage patients (30 stages T1; 38 stages T2) assessed the efficacy of TSI. The average time of treatment was six weeks and after three months from the end of therapy, 97% of patients had complete response. The global survival rates in five and 10 years were 86% and 71%, respectively. Thirty-nine patients (57.4%) had relapse with average disease free interval of 1.8 years. The disease-free survival was 41% and 31% for five and 10 years respectively, being greater when TSI was employed earlier (P = 0.003). After 21 years of follow-up, only one patient developed cutaneous neoplasia (basocellular carcinoma).

Ysebaert et al. [22] in a retrospective study included 141 stages T1 and T2 patients with MF that were treated with TSI. Of these, 25 patients received topical therapy prior to radiotherapy. Energy of 6 MeV was used with daily dose of 2 Gy (4 days/week) and total dose of

*Corresponding author: Gustavo N Marta, Department of Radiotherapy, Sírio-Libanês, Oncology Center, São Paulo, SP, Brazil, E-mail: gnmarta@uol.com.br

Received March 06, 2012; Accepted March 30, 2012; Published April 02, 2012


Copyright: © 2012 Marta GN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
T (skin)

T1 Limited patch/plaque/papules (< 10 percent of total skin surface)
T2 Generalized patch/plaque/papules (>10 percent of total skin surface)
T3 Tumors (≥ 1 cm diameter)
T4 Generalized erythroderma (confluence of erythema covering ≥ 80 percent body surface area)

N (nodes)

N0 Lymph nodes clinically ≤1.5 cm (biopsy not required)
N1 Lymph nodes enlarged clinically, but not involved by histology (includes "reactive" and "dermatopathic" nodes)
N2 Lymph nodes enlarged clinically and abnormal cells are present on histology but they do not efface the nodal architecture.
N3 Lymph nodes enlarged clinically. On histology, there is partial or complete effacement of the nodal architecture by abnormal cells.

M (viscera)

M0 No visceral involvement
M1 Visceral involvement (histologically confirmed)

B (blood)

B0 No circulating atypical (Sezary) cells (<5 percent of lymphocytes)
B1 Circulating atypical (Sezary) cells (5% percent of lymphocytes)
B2 High blood tumor burden: ≥1000/microL Sezary cells with positive clone

Clinical stage

| IA | T1 | N0 | M0 | B0 or B1 |
| IB | T2 | N0 | M0 | B0 or B1 |
| IA | T1 or T2 | N1 or N2 | M0 | B0 or B1 |
| IB | T3 | N0 to N2 | M0 | B0 or B1 |
| IIIA | T4 | N0 to N2 | M0 | B0 |
| IIIB | T4 | N0 to N2 | M0 | B0 |
| IVA1 | T1 to T4 | N0 to N2 | M0 | B2 |
| IVA2 | T1 to T4 | N3 | M0 | B0 to B2 |
| IVB | T1 to T4 | N0 to N3 | M1 | B0 to B2 |

Note: Sezary cells are atypical mononuclear cells with cerebriform nuclei. Their presence in more than 5% in peripheral circulation is used for diagnostic criterion of Sézary’s Syndrome (SS). SS is a leukemic variant of the disease, which, generally, is manifested since its start with erythroderma and goes through usually with diffuse alopecia, palmo-plantar hyperkeratosis and diffuse lymph node access. Patients suffering from SS have worse prognosis.

Table 1: Classification system for mycosis fungoides (TNMB) and Clinical staging system for mycosis fungoides.

30 Gy. Three months after completion of treatment, 87.5% (T1) and 84.8% (T2) had complete response. Treatment failure in one year was 54.4%. From all those that had relapse (31 patients), 18 were submitted to a second course of TSI (24 Gy in 12 fractions) while the remaining 13, to other combined therapies. Local control in five years was greater in the group that received the second course of TSI (70% vs. 39%). For the entire group, the global survival in five, 10 and 15 years was 90%, 65% and 42%, respectively. In univariate analysis, T1 (P = 0.03), complete response after the first course of TSI (P = 0.04) and age under 60 years old (P < 0.001) were prognostic factors for global survival. In multivariate analysis, only patients with age under 60 years old had association with the increase of survival (P = 0.001).

Normally patient submitted to TSI tolerate well the treatment. Meanwhile, the large majority presents some type of side effect, being the most common: erythema, peeling skin with or without ulceration, itch, alopecia, fall of nails, alteration in transpiration with hypohydrosis, edema of hands and feet. In spite that it is rare, cases of gynecomastia in men and epistaxis were already described. In long-term there can be appearance of telangectasia, permanent dystrophy of nails, partial alopecia and secondary squamoproliferative skin neoplasias. Due to low electron penetration, there is no gastrointestinal and hematological toxicity.

After three months from the conclusion of TSI, execution of phototherapy or topical chemotherapy with nitrogenated mustard can be considered as maintenance therapy.

Stage IIIA/IIIB/IV

In patients with advanced disease, introduction of more aggressive therapeutic measures becomes necessary. The treatment options (topical or systemic corticotherapy, topical or systemic chemotherapy, topical or systemic retinoids, phototherapy, chemotherapy, vorinostat, denileukin diftitox, bone marrow transplantation, TSI) vary depending on the characteristics of the presented lesions and on previously employed treatments [18].

In the palliative perspective where there is extensive or recurrent cutaneous and extra cutaneous disease after the first course of TSI there is possibility of repeat irradiation with new TSI plan with substantial benefits and acceptable toxicity rate.

Funk et al. [23] analyzed the efficacy of palliative TSI in 18 patients with advanced stage (stages IIb – V) cutaneous T-cell non-Hodgkin’s lymphoma refractory to previous treatments. The average applied total dose was 25 Gy with average follow-up of 11 months. Fifty percent of patients had complete response; 39%, partial response. The progression free survival in one year was 24% and the global survival in 1 year was 48%. All patients had acute side effects of mild to moderate intensity.

In a study conducted at Yale University (USA), [24] 14 patients received two courses of TSI while five patients, three courses. The median dose used in the first and second course was 36 Gy and 18 Gy respectively. Of the 5 patients who received a total of 3 courses, three received 12 Gy, one received 16 Gy and one received 30 Gy. After the first course of TSI, 93% had complete response; after the second, 86%, after the third, 60%. The median disease free interval after the first course of therapy for those with complete remission was 20 months and 11.5 months after the second course. All patients presented skin-related side effects, with an acceptable risk profile.
Becker et al. [25] in a retrospective analysis studied 15 patients that received second course of TSI. The average dose employed in the first treatment was 32.6 Gy; in the second, 23.4 Gy; the complete and partial response rates after the second course were 40% and 60%, respectively. The observed late toxicity was restricted to drying of skin, telangiectasia, alteration of cutaneous pigmentation and alopecia.

The criteria used for indication of repeat irradiation include the observed clinical response and the disease free interval after the first course of TSI, the area of cutaneous affection and the prior failure of other therapeutic modes. Patients with nodal and/or visceral involvement are often benefited with course of palliative TSI with total dose of 20 to 30 Gy (2 to 3 Gy/fraction).

Conclusions

Radiotherapy is indicated to patients suffering from MF in all stages especially when the disease affects more than 50% of the body surface. Starting from stage IB, TSI is employed with dose of 30 to 36 Gy with boost at medical criterion. Consider phototherapy or topical chemotherapy with nitrogenated mustard as maintenance therapy after three months of TSI. Repeat irradiation is viable, however with treatment doses lower than those employed in the first therapeutic cycle.

Comprehensive Summary

- Indications for radiotherapy: Patients at all stages particularly when the disease affects more than 50% of body surface.
- Area of treatment: From stage IB, the entire body surface.
- Dose: 200 cGy on each side of the body 1000 cGy totaling in 10 days of treatment. Total dose of 3000 to 3600 cGy. Boost the physician’s criteria.
- Consider phototherapy or topical chemotherapy with nitrogen mustard after 3 months of TSI to maintenance therapy.

References